Enzo Biochem: Is This Time Finally Different?

ViktorCap If you're a shareholder of Enzo Biochem (NYSE:ENZ), you're likely frustrated. The investment thesis hasn't changed much in two years; however, shareholders, have been bludgeoned by one thing after another while awaiting Enzo's liquidation following their 2023 sale of the Clinical Labs business to Labocrp Holdings (LH). Is it finally time to buy the beaten-down story, or are investors better off avoiding this mess? There are multiple activists involved in the stock, and the new chairman brings a tr ...